TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Hantavirus Transmission in Households in Chile

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Index Cases:~1. Confirmed diagnosis, positive hantavirus IgM assay or detection of hantavirus in plasma or serum by RT-PCR.~2. Signed informed consent form.~3. Less than 96 hours have transpired since the diagnosis was confirmed.~Household Contact~1. Any person, 2 years of age or older, who has been in close contact with the index case at any point from 30 days before to 7 days after the onset of symptoms in the index case.~2. Close contact must include: sexual contact and/or deep kissing and/or slept in same bed and/or provided direct care to index case.~Exclusion Criteria:~Index Cases~1. Index case does not have or agree to give the names of his/her close contacts.~2. Not a suitable candidate in the opinion of the investigator.~Household Contact~1. Confirmed current or previous infection with Andes virus.~2. Younger than 2 years of age.~3. Unavailable for follow up or not a suitable candidate in the opinion of the investigator.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Effect of Regional Nerve Blocks on Pain and Inflammation After Video Assisted Thorascopic Lung Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than 18~* Planned thoracoscopy with low probability(by surgeon estimate) of conversion to open procedure~Exclusion Criteria:~* Age less than 18~* Clinical or laboratory evidence of systemic infection~* Current pregnancy as assessed by preoperative urine HCG test~* Serious, uncontrolled, non-malignant illness~* Malignant illness requiring systemic chemotherapy in the last 6 months~* Documented allergy to oxycodone, morphine sulfate or acetaminophen~* Contraindication to peripheral nerve blockade or general anesthesia including:~  1. patient refusal~ 2. active infection at site of planned block~ 3. documented allergy to any local or general anesthetic medications~ 4. significant coagulopathy( prothrombin time \>15 seconds, INR\>1.5~ 5. pre-existing neuropathy and medical conditions or deformities which would compromise block or anesthetic safety~* Planned pleurodesis~* Current use of high dose inhaled or systemic steroids~* Current use of Amiodarone (Cordarone)~* Morbid obesity (BMI=40kg/m2)~* Patients with clinically significant mental health issues such as psychosis requiring treatment with antipsychotic medications.~* Patients unable to consent~* Patients with active infections requiring antibiotics within one month of registration~* Participation in other clinical trials that may interfere with this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Patients randomized to receive thoracic paravertebral nerve blockade in addition to general endotracheal anesthesia during video assisted thoracoscopy procedure
- B (Type: SHAM_COMPARATOR): Patients randomized to receive sham single-injection thoracic peripheral nerve blockade (no injection) in addition to general endotracheal anesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Rectal Cancer Treatment Response Using PET/MRI

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of histopathologically confirmed rectal adenocarcinoma.~* Locally advanced disease as determined by ERUS or pelvic MRI. Endoscopy reports should clearly state both the T and N stage.~* Patients with cT2N1-3M0 or cT2-4NxM0 will be considered eligible for participation.~* Age ≥18.~* Ability to understand a written informed consent document and the willingness to sign it.~* Tumor must be determined to be surgically resectable. Surgical resection is planned to take place at Univeristy of California, San Francisco (UCSF).~* Neoadjuvant chemoradiation prior to resection is planned..~* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.~Exclusion Criteria:~* ERUS tumor state of T1.~* Radiographic evidence of metastatic disease~* Weight in excess of limitations of the scanner or girth that prohibits entry into the bore of the PET/CT scanner due to size.~* Any medical condition which impairs the ability to lie flat and without movement for 15 minutes (e.g. cough, severe arthritis, etc.)~* Prior receipt of any therapy, including local excision, radiation or chemotherapy, for the diagnosed rectal adenocarcinoma.~* Prior history of pelvic radiation.~* Uncontrolled hyperglycemia (defined as inability to achieve a glucose of \<250 mg/dL at time of fluorodeoxyglucose (FDG) injection).~* Impaired renal function (CKD 4 or 5: estimated glomerular filtration rate (eGFR) \< 30 mLs/min), which is a contraindication to gadolinium containing contrast.~* Known allergy to gadolinium containing contrast agents.~* Contraindication to use of fluoropyrimidines as a radiosensitizing agent.~* Pregnancy or nursing. Women of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to randomization. This is because of the potential teratogenic effects of the involved imaging modalities, radiation, and chemotherapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adjuvant chemotherapy (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of a Strategy and Computer-based Intervention to Enhance Daily Cognitive Functioning After Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* History of first-time stroke, minimum of 6 months prior to enrollment~* English speaking~* Ability to comprehend sufficiently to participate in the treatment.~* Subjective or objective evidence of mild cognitive impairment~* Willingness to participate in full study duration~* Has computer that meets specification for the training program software.~* Physically able to operate a computer keyboard and mouse.~* Not concurrently receiving other cognitive rehabilitation services~* Cognitively able to perform basic self-care activities (e.g., dressing, grooming, eating).~Exclusion Criteria:~* History of neurologic disease other than stroke~* History of severe mental illness or substance use disorder, or current major depressive episode.~* History of dementia or dependence in basic self-care activities due to cognitive deficits~* Contraindications to MRI

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- ASCEND (Type: EXPERIMENTAL): ASCEND combines computer-based cognitive training exercises, homework exercises to enhance cognition, and coaching sessions delivered in-person and via telephone/videoconference by a neuropsychologist. ASCEND includes 24 total computer training sessions of 30 minutes each, for a total of 12 hours. ASCEND includes 8 coaching sessions of 45 minutes each. The computer exercises aim to improve attention, working memory (WM), and cognitive control through a series of engaging and interactive computer games (e.g., card games, driving simulation). The homework exercises and coaching sessions aim to assist the participant in generalizing and transferring skills from the computer exercises to daily life and to develop further strategies to compensate for attention and WM difficulties in daily life.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has histologically or cytologically confirmed, unresectable and/or metastatic GIST~* Participant has measurable disease~* Participant has documented objective progression following, or intolerance to, treatment with both imatinib and sunitinib~* Participant's Eastern Cooperative Oncology Group (ECOG) performance status (PS) is 0 to 2~* Participant has either:~  1. prior results from growth factor receptor associated with tyrosine kinase activity (KIT) and PDGFRα mutation analysis that meet analytical criteria as defined for the on-study analysis of these mutations and tumor tissue (from either primary or metastatic tumor) that can be submitted for analysis within 30 days after the first dose of study therapy; or~ 2. if prior results from KIT and PDGFRα mutation analysis are not available or do not meet analytical criteria as above, then tumor tissue (from either primary or metastatic tumor) must be submitted for genotype testing at the latest 28 days prior to the first dose of study therapy~* Participant has adequate hematologic, hepatic, renal and coagulation function~* Women of childbearing potential and sexually active males must agree to use adequate contraception prior to study and for at least 12 weeks after the last dose of IMC-3G3~* Participant has a life expectancy of ≥ 3 months~Exclusion Criteria:~* Participant has untreated central nervous system metastases, and as a result, is clinically unstable with regard to neurologic function~* Participant has a history of another primary cancer~* Participant has received any investigational therapy within 14 days prior to registration, or is currently enrolled in any other type of medical research~* Participant is receiving concurrent treatment with other anticancer therapy~* Participant has known human immunodeficiency virus (HIV) infection~* Participant has undergone major surgery within 28 days prior to registration~* If female, participant is pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PDGFRα mutation negative (Type: EXPERIMENTAL): Participants with GIST with genotypes that do not have a PDGFRα mutation given 20 milligrams per kilogram (mg/kg) Olaratumab intravenously (IV) every 14 days.
- PDGFRα mutation positive (Type: EXPERIMENTAL): Participants with GIST with genotypes that have a PDGFRα mutation given 20 mg/kg Olaratumab IV every 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: REMission INDuction in Very Early Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fulfilling 2010 ACR/EULAR criteria for RA.~* Patient reported symptom duration \< 12 months~* Naïve for DMARD and biological treatment~* Naïve for previous use of glucocorticoids for RA~* DAS28 ≥3.2~Exclusion Criteria:~* Being pregnant or being a nursing women or a women of child bearing potential without (adequate) use of contraception~* Having any other inflammatory rheumatic disease than RA, except for secondary Sjögren's syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Taper methotrexate, then golimumab (Type: EXPERIMENTAL): Taper methotrexate 25\>0mg/wk during 24 weeks, then, if still in sustained remission, taper golimumab 50\>0mg/month during 24 weeks.
- Taper golimumab, then methotrexate (Type: ACTIVE_COMPARATOR): Taper golimumab 50\>0mg/month during 24 weeks, then, if still in sustained remission, taper methotrexate 25\>0mg/wk during 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of metastatic breast cancer.~* Participants must have completed first line of metastatic chemotherapy and have achieved complete or partial response or disease stability for at least 6 months from the first confirmation of disease stabilization.~* No clinical sign of brain progression.~* At least one of the following 3 conditions: HER2 +++, Young age (\< 50 years), and/or estrogen receptor (ER)-/progesterone receptor (PgR)-~* Eastern Cooperative Oncology Group (ECOG) performance status ≤2.~* Life expectancy ≥3 months.~* Neutrophils ≥1.5 x 10\^9/L, platelets ≥100 x 10\^9/L, hemoglobin ≥9 g/dL, lymphocytes ≥1 x 10\^9/L.~* Bilirubin level either normal or \<1.5 x ULN (upper limit of normal).~* AST (aspartate aminotransferase) and ALT (alanine aminotransferase) ≤2.5 x ULN (≤5 x ULN if liver metastases are present).~* Serum creatine \<1.5 x ULN.~* Effective contraception if the risk of conception exists.~Exclusion Criteria:~* Concurrent chronic systemic immune therapy not indicated in the study protocol.~* Any investigational agent(s) within 4 weeks prior to entry.~* Participants that have completed 2nd, 3rd, or 4th line metastatic chemotherapy or participant in active chemotherapy treatment.~* Clinically relevant coronary artery disease or a history of a myocardial infarction within the last 12 months.~* Acute or sub acute intestinal occlusion or history of inflammatory bowel disease.~* Known Grade 3 or Grade 4 allergic reaction to any of the components of the treatment.~* Known drug abuse/alcohol abuse.~* Legal incapacity or limited legal capacity.~* Medical or psychological condition which in the opinion of the investigator would not permit the participant to complete the study or sign meaningful informed consent.~* Women who are pregnant or breastfeeding.~* Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of the cervix (participants with a previous malignancy but without evidence of disease for ≥5 years will be allowed to enter the trial).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Temozolomide (Type: EXPERIMENTAL): None
- Observational (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Exposure to Type II Diabetes for Two Siblings With the Same Parents

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* You are one of a sibling pair with the same mother and father, and your mother had diabetes (gestational or type 2) while she was pregnant with the younger sibling but not the older sibling.~* Your sibling is willing to participate in the study.~* You are between the ages of 20 and 34 years (inclusive)~* Your body mass index is between 20 and 29 Kg/m2 inclusive (this is a number calculated for your height and weight and indicates that you are either normal weight or overweight, but not obese).~* You are healthy as assessed by medical history and standard physical examination~* You are weight stable (your body weight has not changed .6.5 lbs over the last 3 months).~* You do not smoke~* You provide written informed consent to participate in the study.~* You are willing to stay overnight one time at the Pennington Center.~* You have low physical activity (\< 100 min of exercise per week).~Exclusion Criteria:~* You were born prematurely (\<37 weeks of pregnancy)~* You are currently taking medication that may influence your body weight or metabolism.~* You have heart disease, lung disease, liver disease, blood disease, kidney disease, type 1 or 2 diabetes, or any other disease that in the opinion of the doctor might make you ineligible.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 34 Years
- Healthy Volunteers: t

Study Arms:
- Exposure to Type II Diabetes for two siblings (Type: None): Two sibling pairs with the same parents, between the ages of 20 to 34 in the Baton Rouge Area, having mother with diabetes while pregnant with one.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial of NanoPac Focal Therapy for Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age;~* Histopathologically proven adenocarcinoma of the prostate:~  * Localized cancer;~ * Subjects with tumors classified as \<T3 per TNM classification, Gleason score≥ 6;~* Prostate tumor must be able to be visualized on mpMRI;~* Already considered to be candidate for radical prostatectomy;~* Considered appropriate for treatment with paclitaxel therapy;~* Laboratory requirements:~  * WBC \>2500/mm3~ * Neutrophil \>1500/mm3~ * Hemoglobin \>10 mg/dL~ * Platelet \>100,000/ mm3~ * AST and ALT \<2.5 x ULN~ * Total bilirubin \<1.5 x ULN~ * Calculated creatinine clearance ≥ 30 ml/min~ * Normal PT/INR and PTT;~* ECOG of 0 or 1;~* International Prostate Symptom Score (I-PSS) less than or equal to 20;~* If sexually active, willing to use double condoms from time of NanoPac injection until prostatectomy;~* Agree to all study procedures and provide signed informed consent;~Exclusion Criteria:~* Evidence of locally advanced or metastatic disease;~* Prostate size ≥ 50 cc;~* Prior prostatectomy, including surgery for any benign condition (such as TURP);~* Anticipated use of concomitant chemotherapy (other than the protocol specified agents), immunotherapy, or systemic use of hormonal therapy (such as GnRH analogs, antiandrogens, androgen receptor inhibitors, and 5-α reductase inhibitors) while on study prior to surgery;~* Treatment with a prior investigational medication within 30 days of first dose of study agent;~* Any previous local treatment of the prostate (e.g. radiation, HIFU, cryotherapy, Focal Irreversible Electroporation, Photodynamic Therapy, Laser Induced Thermometry);~* Any other condition (e.g., psychiatric disorder) that, in the opinion of the Investigator, may interfere with the subject's ability to comply with the study requirements or visit schedule;~* Known sensitivity to any of the study agent components;~* History of prior malignancy that has not been in remission for \>5 years, with the exception of basal cell or squamous cell carcinoma.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NanoPac (Type: EXPERIMENTAL): Direct injection of NanoPac at 15 mg/mL at a volume not to exceed the volume of the prostate cancer lesion (no more than 10% of total prostate volume). NanoPac will be administered on up to three occasions, with at least 28 days between each dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Oxygen Controllers in Preterm InfanTs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Preterm infants with a gestational age (GA) at birth of 24 - 29+6/7 weeks~* Receiving invasive mechanical ventilation or non-invasive respiratory support (NCPAP or NIPPV)~* Receiving supplemental oxygen (defined as FiO2 ≥ 0.25) at the time of enrollment and for at least 18 hours during the previous 24 hours; Or a coefficient of variation in supplemental oxygen of ≥ 0.1 in the previous 24 hours.~* Expected to complete the 49-hour or 50-hour study period in the current form of respiratory support, i.e. invasive mechanical ventilation or non-invasive respiratory support~* Written informed parental consent must be present.~Exclusion Criteria:~* Major congenital anomalies~* Arterial hypotension requiring vasopressor therapy within 48 hours prior to enrollment.~* If the attending physician considers the infant not stable enough for a switch to another ventilator.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 8 Weeks
- Healthy Volunteers: f

Study Arms:
- CLiO2 (Type: EXPERIMENTAL): Automated oxygen control by the CLiO2 algorithm
- Oxygenie (Type: EXPERIMENTAL): Automated oxygen control by the Oxygenie algorithm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues